RxSight, Inc.
RXST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 57.1% | 81.8% | 116.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 70.7% | 60.4% | 43.5% | 20% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -17% | -46.1% | -117.9% | -181.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -19.6% | -54.6% | -136.2% | -215.5% |
| EPS Diluted | -0.71 | -1.41 | -2.41 | -1.78 |
| % Growth | 49.6% | 41.5% | -35.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |